Enterprise Value

-3.111B

Cash

3.449B

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

0.75%

Institutional Own.

64.05%

Qtr Updated

12/31/22


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

BLA

Submission

TJ101 (Eftansomatropin alfa) Details
Pediatric growth hormone deficiency

Big Mover™

Susp. Mover™

Phase 3

Data readout

Lemzoparlimab Details
High risk myelodysplastic syndromes

Phase 3

Update

TJ301 (Olamkicept) (gp130 IL-6 inhibitor) Details
Ulcerative colitis, Autoimmune disease

Phase 3

Update

Phase 2

Data readout

TJ107 (Efineptakin alfa) (IL-7) Details
Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma

Phase 2

Data readout

uliledlimab (TJD5) (TJ004309) (anti-CD73) (+ atezolizumab (TECENTRIQ®)) Details
Cancer, Non-small cell lung carcinoma

Big Mover™

Susp. Mover™

Phase 2

Data readout

MOR210 (TJ210) Details
Solid tumor/s, Cancer

Phase 1

Data readout

Enoblituzumab (TJ271) + Pembrolizumab Details
Head and neck cancer, Cancer, Prostate cancer, Solid tumor/s

Failed

Discontinued